|
TW202043267A
|
|
Ltbp complex-specific inhibitors of tgfβ and uses thereof
|
|
WO2020086736A1
|
|
Rgmc-selective inhibitors and use thereof
|
|
US2021122814A1
|
|
HIGH-AFFINITY, ISOFORM-SELECTIVE TGFß1 INHIBITORS AND USE THEREOF
|
|
WO2020014473A1
|
|
TGFβ1 INHIBITORS AND USE THEREOF
|
|
EP3677278A1
|
|
Isoform selective tgfbeta1 inhibitors and use thereof
|
|
AR115755A1
|
|
ISOFORM SELECTIVE HIGH AFFINITY TGFb1 INHIBITORS AND THEIR USES
|
|
AR115756A1
|
|
TGFb1 INHIBITORS AND USE OF THEM
|
|
EP3658583A1
|
|
Ltbp complex-specific inhibitors of tgf-beta 1 and uses thereof
|
|
AU2018266784A1
|
|
LRRC33 inhibitors and use thereof
|
|
WO2018129395A1
|
|
Methods for treating metabolic diseases by inhibiting myostatin activation
|
|
CN110382530A
|
|
Hypospecificity, 1 inhibitor of background permissive TGF β and application thereof
|
|
AU2018205270A1
|
|
Methods for treating metabolic diseases by inhibiting myostatin activation
|
|
EP3484499A1
|
|
Tgfb antibodies, methods, and uses
|
|
HUE051480T2
|
|
Use of myostatin inhibitors and combination therapies
|
|
MX2018010948A
|
|
TGFß1-BINDING IMMUNOGLOBULINS AND USE THEREOF.
|
|
AU2017206069A1
|
|
Anti-pro/latent myostatin antibodies and methods of use thereof
|
|
WO2017075037A1
|
|
Primed growth factors and uses thereof
|
|
KR20180049075A
|
|
Anti-pro / latency-myostatin antibody and uses thereof
|
|
WO2017015622A2
|
|
Gdf11 binding proteins and uses thereof
|
|
WO2016073879A2
|
|
Transforming growth factor-related antibodies and uses thereof
|
